Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 3370
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT07840027 Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-0… |
TRB-001 | Parkinson | Phase 1 | RECRUITING | En attente / non publié | Tridem Bioscience FlexCo | Austria · PROSENEX Studienzentrum an der ATOMOS Klini… | 2026-09 → 2028-09 | Ouvrir |
| NCT07839793 FLORA — A 12-Week Study of Flexilev With the OraFID Device and App in P… |
OraFID dosing device, Levodopa/Ca… | Parkinson | Phase 4 | RECRUITING | En attente / non publié | Navamedic AB | Sweden · Centrum för Neurologi, Stockholm, Sweden | K… | 2026-05-25 → 2027-06-30 | Ouvrir |
| NCT06891781 ADVENT — Investigating Adaptive Deep Brain Stimulation in Parkinson's D… |
Deep Brain Stimulation | Parkinson | Non applicable | RECRUITING | En attente / non publié | Boston Scientific Corporation | Italy · IRCCS San Gerardo dei Tintori, Monza, Italy | 2026-08-26 → 2029-08 | Ouvrir |
| NCT07839481 tcVNS-PD — Effects of Transcutaneous Cervical Vagus Nerve Stimulation o… |
transcutaneous vagus nerve stimul… | Parkinson | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Kyoungwon Baik | Non communiqué | 2026-09-30 → 2027-06-30 | Ouvrir |
| NCT04626518 Substudy 03B: A Study of Immune and Targeted Combination Therapies in P… |
Pembrolizumab | Parkinson | Phase 1/2 | COMPLETED | En attente / non publié | Merck Sharp & Dohme LLC | United States, Australia, Canada, Chile, France, Hung… | 2020-12-17 → 2026-07-23 | Ouvrir |
| NCT04626479 Substudy 03A: A Study of Immune and Targeted Combination Therapies in P… |
Pembrolizumab | Parkinson | Phase 1/2 | COMPLETED | En attente / non publié | Merck Sharp & Dohme LLC | United States, Australia, Canada, Chile, Colombia, Fr… | 2020-12-16 → 2026-08-10 | Ouvrir |
| NCT07569133 Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving … |
Repetitive Transcranial Magnetic … | Parkinson | Non applicable | ENROLLING_BY_INVITATION | En attente / non publié | Chi-Ying (Roy) Lin | South Korea · Kyungpook National University Chilgok h… | 2026-05-04 → 2026-12-31 | Ouvrir |
| NCT05164783 EPD — Multicenter Implementation of E-monitoring in Parkinson's Disease |
Sanacoach Parkinson (SCP) | Parkinson | Non applicable | COMPLETED | En attente / non publié | Zuyderland Medisch Centrum | Netherlands · Elkerliek Hospital, Helmond, Netherland… | 2021-11-23 → 2025-07-27 | Ouvrir |
| NCT06466525 A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tole… |
LBT-3627 | Parkinson | Phase 1 | RECRUITING | En attente / non publié | Longevity Biotech Australia Pty L… | Australia · Alfred Hospital, Melbourne, Australia | M… | 2024-07-16 → 2027-02 | Ouvrir |
| NCT03332121 B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma |
B001 | SEP | Phase 1 | COMPLETED | En attente / non publié | Shanghai Pharmaceuticals Holding … | China · Institute of Hematology and Blood Disease Hos… | 2018-03-22 → 2021-02-28 | Ouvrir |
| NCT04660799 A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (… |
Rituximab IV | SEP | Phase 2 | COMPLETED | En attente / non publié | Hoffmann-La Roche | China · Fujian Provincial Cancer Hospital, Fuzhou, Ch… | 2021-02-24 → 2022-10-11 | Ouvrir |
| NCT00244985 Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed … |
Rituximab | SEP | Phase 1/2 | COMPLETED | En attente / non publié | National Cancer Institute (NCI) | United States · Roswell Park Cancer Institute, Buffal… | 2005-09 → 2012-12 | Ouvrir |
| NCT00244855 Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hod… |
Rituximab | SEP | Phase 2 | COMPLETED | En attente / non publié | National Cancer Institute (NCI) | United States · Fred Hutchinson Cancer Research Cente… | 2004-05 → 2011-08-29 | Ouvrir |
| NCT05878184 Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) |
SC291 | SEP | Phase 1 | ACTIVE_NOT_RECRUITING | En attente / non publié | Sana Biotechnology | United States, Australia · City of Hope, Duarte, Unit… | 2023-05-02 → 2038-11-04 | Ouvrir |
| NCT02992834 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for C… |
IL-2 pre-treated CD19 cells | SEP | Phase 4 | UNKNOWN | En attente / non publié | jiangjingting | China · First People's Hospital of Changzhou, Changzh… | 2016-12 → 2022-01 | Ouvrir |
| NCT07367685 Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatmen… |
QH103 Cell Injection | SEP | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | The Second Affiliated Hospital of… | China · The Second Affiliated Hospital of Fujian Medi… | 2026-05-01 → 2028-12-31 | Ouvrir |
| NCT04806347 Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Rela… |
TCRαβ+/CD19+ depleted Hematopoiet… | SEP | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | University of Wisconsin, Madison | Non communiqué | 2026-09 → 2030-06 | Ouvrir |
| NCT02143414 Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and… |
Biopsy Procedure | SEP | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · Ascension Via Christi Hospitals Wichi… | 2015-06-30 → 2027-06-06 | Ouvrir |
| NCT02427776 SCLEROLYM — A Trial for Evaluating Both Safety and Preliminary Efficacy… |
Autologous CD4+T cells stimulated… | SEP | Phase 1/2 | TERMINATED | En attente / non publié | Imcyse SA | Belgium · Cliniques universitaires Saint-Luc, Brussel… | 2015-01 → 2016-08 | Ouvrir |
| NCT01895439 Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cel… |
Autologous Mesenchymal Stem Cells | SEP | Phase 1/2 | COMPLETED | En attente / non publié | University of Jordan | Jordan · Cell Therapy Center, Jordan University Hospi… | 2012-10 → 2016-02 | Ouvrir |
| NCT05893225 Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain… |
Metformin Hydrochloride 850 mg Or… | SEP | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | University Hospital, Antwerp | Belgium · Antwerp University Hospital, Edegem, Belgiu… | 2023-11-23 → 2027-02-28 | Ouvrir |
| NCT07304024 CAPD-LOOT — A Treatment for a Form of Age-Related Central Auditory Proc… |
Clemastine Fumarate Combined With… | SEP | Phase 1/2 | RECRUITING | En attente / non publié | University of Colorado, Denver | United States · University of Colorado Anschutz Medic… | 2025-03-31 → 2028-07 | Ouvrir |
| NCT06330077 MODIF-MS — Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sc… |
Ifenprodil | SEP | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | Assistance Publique - Hôpitaux de… | France · Groupe Hospitalier Pitié Salpêtrière - APHP,… | 2024-03 → 2027-06 | Ouvrir |
| NCT01451593 Neuroprotection With Phenytoin in Optic Neuritis |
Phenytoin | SEP | Phase 2 | COMPLETED | En attente / non publié | University College, London | United Kingdom · National Hospital For Neurology and … | 2011-11 → 2015-03 | Ouvrir |
| NCT03562975 Upper Extremity Function in Multiple Sclerosis Patients With Advanced D… |
Ocrelizumab | SEP | À vérifier | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States · Carol and Frank Morsani Center for Ad… | 2018-07-23 → 2023-01-11 | Ouvrir |